资讯

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class ...

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic ...